{"id":"NCT04994483","sponsor":"Cassava Sciences, Inc.","briefTitle":"Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-03","primaryCompletion":"2024-10-02","completion":"2024-10-02","firstPosted":"2021-08-06","resultsPosted":"2025-05-25","lastUpdate":"2025-05-25"},"enrollment":804,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"Simufilam","otherNames":["PTI-125"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Simufilam 100 mg","type":"EXPERIMENTAL"}],"summary":"A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. Approximately 750 participants will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.","primaryOutcome":{"measure":"Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)","timeFrame":"Baseline (Study Day 1) to Week 52","effectByArm":[{"arm":"Simufilam 100 mg","deltaMin":2.79,"sd":0.363},{"arm":"Placebo","deltaMin":3.19,"sd":0.359}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4308"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Australia","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":399},"commonTop":["COVID-19","Fall","Urinary tract infection","Diarrhoea","Headache"]}}